New drug combo shows promise in shrinking breast tumors before surgery
NCT ID NCT02562118
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a combination of two drugs, lenvatinib and letrozole, given before surgery to postmenopausal women with a common type of breast cancer (hormone receptor positive). The goal is to see if the drugs can shrink the tumor enough to improve surgical outcomes. About 40 women will take part, first to find the safest dose, then to measure how well the treatment works.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National University Hospital
Singapore, Singapore, 119228, Singapore
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a radioactive tracer pinpoint Cancer's first stop?
- Can a personalized exercise program boost recovery in cancer survivors?
- Smartwatch could spot nerve damage before it starts
- Could ionized gas help fight breast cancer after surgery?
- Radiation may let breast cancer patients keep their nipple
- Can a smart digital program restore sleep for cancer survivors?